Refer a Patient Request an Appointment
Adel M. Malek, MD, PhDNeurovascular Surgery · Boston

2026 · Devices & clinical

Post-approval study 3-year outcomes of the Neuroform Atlas stent for the treatment of wide-necked intracranial aneurysms

Jankowitz B, Jadhav AP, Gross B, Jovin TG, Alhajeri AA, Fraser JF, Hanel RA, Sauvageau E, Aghaebrahim A, Frei D, Bellon R, Loy DN, Puri AS, Malek AM, Thomas AJ, Toth G, Lopes DK, Crowley RW, Reavey-Cantwell J, Lin E, Siddiqui A, Alexander MJ, Khaldi A, Colby GP, Caplan JM, Satti SR, Turk AS, Spiotta AM, Klucznik R, Hallam DK, Kung D, Froehler MT, Callison RC, Kan P, Hetts SW, Price LL, Zaidat OO, ATLAS Investigators.

J Neurointerv Surg, 2026.

PMID 41617495 · DOI 10.1136/jnis-2025-024547

In plain language

The Neuroform Atlas is a small stent used to hold platinum coils inside wide-necked brain aneurysms. This study followed patients from the ATLAS trial for three years after treatment.

Share of aneurysms completely closed on follow-up imaging at 2 and 3 years, for aneurysms in the front and back of the brain. Numbers show aneurysms closed out of those imaged.
Share of aneurysms completely closed on follow-up imaging at 2 and 3 years, for aneurysms in the front and back of the brain. Numbers show aneurysms closed out of those imaged.Chart drawn for this site from data in Jankowitz B et al. J Neurointerv Surg, 2026.

Among patients with aneurysms in the front of the brain, 96% of those imaged at three years had complete aneurysm closure, compared with 79% of those with aneurysms in the back of the brain. A major stroke on the treated side or death from neurological causes occurred in about 4 to 5% of patients over the three years, and no treated aneurysm bled after the first year.

The results support the long-term safety and durability of this treatment.

A plain-language summary for patients and families. It is not medical advice, and individual results vary.

Abstract

Introduction

The ATLAS trial was a prospective, multicenter, single-arm, investigational device exemption (IDE) study to evaluate the safety and effectiveness of the Neuroform Atlas Stent System for the treatment of wide-necked bifurcation aneurysms. This analysis presents the 36-month follow-up data for the anterior and posterior cohorts.

Methods

Of the 182 patients in the IDE anterior cohort, 146 consented to participate in the post-approval study (PAS) and, of the 116 patients in the IDE posterior cohort, 101 consented to participate in the PAS. The primary effectiveness endpoint was core laboratory adjudicated (Raymond-Roy 1; RR1) without retreatment or parent artery stenosis (>50%) at 36 months post-procedure. The primary safety endpoint was Clinical Event Committee-adjudicated major ipsilateral stroke or neurological death through 36 months.

Results

There were 146 patients in the anterior cohort and 101 patients in the posterior cohort. At 24 months the composite effectiveness endpoint was 77.3% (34/44) in the anterior cohort and 65.5% (19/29) in the posterior cohort and at 36 months these rates were 92.3% (24/26) and 75.0% (18/24), respectively. RR1 rates at 24 months were 84.1% (37/44) in the anterior cohort and 70.0% (21/30) in the posterior cohort; at 36 months they were 96.3% (26/27) and 79.2% (19/24), respectively. By 36 months the primary safety endpoint occurred in 4.1% (6/146) of patients in the anterior cohort and 5.0% (5/101) in the posterior cohort.

Conclusion

The results of the long-term assessment of the Neuroform Atlas Stent System demonstrate favorable safety and effectiveness in the treatment of wide-necked bifurcation aneurysms without a single treated target aneurysm rupture beyond 12 months post-procedure.

Abstract as indexed in PubMed (PMID 41617495). Copyright the publisher.

Cite this paper

Jankowitz B, Jadhav AP, Gross B, Jovin TG, Alhajeri AA, Fraser JF, Hanel RA, Sauvageau E, Aghaebrahim A, Frei D, Bellon R, Loy DN, Puri AS, Malek AM, Thomas AJ, Toth G, Lopes DK, Crowley RW, Reavey-Cantwell J, Lin E, Siddiqui A, Alexander MJ, Khaldi A, Colby GP, Caplan JM, Satti SR, Turk AS, Spiotta AM, Klucznik R, Hallam DK, Kung D, Froehler MT, Callison RC, Kan P, Hetts SW, Price LL, Zaidat OO, ATLAS Investigators. Post-approval study 3-year outcomes of the Neuroform Atlas stent for the treatment of wide-necked intracranial aneurysms. J Neurointerv Surg. 2026. doi:10.1136/jnis-2025-024547 PMID: 41617495.